Literature DB >> 2190791

Pharmacological treatment of patients with schizophrenia. Past and present problems and potential future therapy.

D A Johnson1.   

Abstract

Entities:  

Mesh:

Year:  1990        PMID: 2190791     DOI: 10.2165/00003495-199039040-00001

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


× No keyword cloud information.
  51 in total

1.  Observations on the dose regime of fluphenazine decanoate in maintenance therapy ofschizophrenia.

Authors:  D A Johnson
Journal:  Br J Psychiatry       Date:  1975-05       Impact factor: 9.319

2.  Psychotic exacerbations produced by neuroleptics.

Authors:  G M Simpson; E Varga; J Haher
Journal:  Dis Nerv Syst       Date:  1976-07

3.  Targeted treatment of depression-like symptoms in schizophrenia.

Authors:  S G Siris; F Adan; M Cohen; J Mandeli; A Aronson; B Fasano-Dube
Journal:  Psychopharmacol Bull       Date:  1987

Review 4.  Observations on the use of long-acting depot neuroleptic injections in the maintenance therapy of schizophrenia.

Authors:  D A Johnson
Journal:  J Clin Psychiatry       Date:  1984-05       Impact factor: 4.384

5.  Aspects of clinical psychiatric research on depot neuroleptics. The presentation of two double-blind trials with cis(z)-clopenthixol decanoate and a withdrawal study in schizophrenics.

Authors:  S J Dencker; K Elgen
Journal:  Acta Psychiatr Scand Suppl       Date:  1980

6.  Why do schizophrenic patients refuse to take their drugs?

Authors:  T Van Putten
Journal:  Arch Gen Psychiatry       Date:  1974-07

7.  High doses of fluphenazine enanthate in schizophrenia. A controlled study.

Authors:  S J Dencker; R Johansson; L Lundin; U Malm
Journal:  Acta Psychiatr Scand       Date:  1978-05       Impact factor: 6.392

8.  The Northwick Park "functional" psychosis study: diagnosis and treatment response.

Authors:  E C Johnstone; T J Crow; C D Frith; D G Owens
Journal:  Lancet       Date:  1988-07-16       Impact factor: 79.321

9.  A depot neuroleptic withdrawal study. A controlled study of the clinical effects of the withdrawal of depot fluphenazine decanoate and depot flupenthixol decanoate in chronic schizophrenic patients.

Authors:  B Wistedt
Journal:  Acta Psychiatr Scand       Date:  1981-07       Impact factor: 6.392

10.  Haloperidol. Plasma levels and prolactin response as predictors of clinical improvement in schizophrenia: chemical v radioreceptor plasma level assays.

Authors:  R C Smith; R Baumgartner; C H Misra; M Mauldin; A Shvartsburd; B T Ho; C DeJohn
Journal:  Arch Gen Psychiatry       Date:  1984-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.